Please login to the form below

Not currently logged in

New Pfizer UK leader as Nordkamp moves into European role

Ben Osborn to take on managing director role

Pfizer has a new UK leader, following the move of current managing director Erik Nordkamp to a European role.

Longstanding Pfizer executive Ben Osborn will take on the UK managing director in the UK, while Nordkamp will retain a UK general manager title, but will also be Cluster Lead Europe within Pfizer’s Established Medicines business.

The changes reflect a wider reorganisation in Pfizer's US headquarters, where Albert Bourla will succeed Ian Read as CEO of Pfizer on 1 January, plus a reshuffle of the company's portfolios and most senior execs.

Erik has been Pfizer’s managing director for almost four years, and during this time, he has also chaired the American Pharmaceutical Group (APG) and is the current President of the Association of the British Pharmaceutical Industry (ABPI).

This has given him a central role in the dialogue with the UK government and the NHS, including on key issues such as the Life Science Sector Deal, negotiations for the newly agreed 2019 Voluntary Scheme for Branded Medicines Pricing and Access (formerly known as the PPRS) and, of course, Brexit.


Erik Nordkamp

“It has been a tremendous privilege to lead the UK Company and while it has undoubtedly been challenging, it has also been immensely rewarding,” said Erik.

“Pfizer is committed to partnering with the NHS to improve the delivery of healthcare and achieve the best health outcomes for people in the UK.  We must all work together to create an innovation-ready health service by finding new ways to embrace next-generation ideas and technologies that can transform care and improve lives while creating efficiencies within the health system”.

Ben Osborn

Pfizer UK's new managing director Ben Osborn

Ben Osborn joined Pfizer in 1998 and has been leading the marketing organisation within Pfizer’s Innovative Medicines business at a regional level since 2015.  Prior to this, he was Head of Pfizer Oncology in the UK where he assisted in shaping UK cancer policy through his work with government, patient groups and as a co-chair of the ABPI’s cancer group.  He also sat on the NHS Molecular Diagnostics in Cancer working group, as well as the South London Academic Health Science Network.

Commenting on his appointment, Ben said: “I am delighted to be returning to the UK business and to be taking on the role of UK Managing Director at such an important time.  With the NHS at a critical moment in the development of its long-term plan, a new era of partnership between the health service and industry will be vital to achieving the best for UK patients.  We are, therefore, very keen to develop new and build on existing relationships with Government and the NHS to try and help deliver this”.

Erik will continue to be based in the UK and will remain as ABPI President until April 2019, when the ABPI’s next Annual General Meeting takes place.

Article by
Andrew McConaghie

10th December 2018

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Dimitri Azzopardi
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day...
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes....
Interim analysis clinical trials
Assessing the value of interim analyses in clinical trials
Why its important and when its needed...